COLO B Coloplast A/S Class B

Coloplast A/S - FY 2023/24 Earnings Release - Invitation for conference call on 5 November 2024 at 11.00 CET

Coloplast A/S - FY 2023/24 Earnings Release - Invitation for conference call on 5 November 2024 at 11.00 CET

Tuesday, 5 November 2024 at 11.00 – 12.00 CET

In connection with the publication of Coloplast's interim financial results for FY 2023/24 the company will host a conference call to present the financial results and answer questions from investors and financial analysts.

A presentation will be available on Coloplast's website approximately 1 hour before the conference call.

Please note that the webcast of the conference call will be available during and after the event.



Coloplast will be represented by:

Kristian Villumsen - President & CEO

Anders Lonning-Skovgaard - Executive Vice President, CFO

Aleksandra Dimovska - Vice President, Investor Relations

Kristine Husted Munk - Senior Manager, Investor Relations 



Webcast

Any participants who do not wish to actively participate in the question & answer session, please access the conference call as a webcast directly by clicking here:

 



Dial-in details

For analysts and any participants wishing to actively participate in the question & answer session please sign up ahead of the conference call on the link below to receive an email with dial-in details: 

 

For more information, please contact:

Aleksandra Dimovska, Vice President, Investor Relations

Tel.: / direct: , e-mail: 

Kristine Husted Munk, Senior Manager, Investor Relations

Tel.: / direct: , e-mail: 

Julie Sommer Müggler, Coordinator & PA, Investor Relations

Tel.: / direct: , e-mail:

Konstancija Norvilaite, Associate IR & Finance Manager, Investor Relations

Tel.: / direct: , e-mail:



 

Coloplast will be available on individual phone lines after the conference call for further questions.

Attachment



EN
21/10/2024

Underlying

COLO BColoplast A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
COLO B COLOPLAST A/S CLASS B
6h / 17m 6h / 17m 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - FY 2023/24 Earnings Release - Invitation for conferenc...

Coloplast A/S - FY 2023/24 Earnings Release - Invitation for conference call on 5 November 2024 at 11.00 CET Tuesday, 5 November 2024 at 11.00 – 12.00 CETIn connection with the publication of Coloplast's interim financial results for FY 2023/24 the company will host a conference call to present the financial results and answer questions from investors and financial analysts.A presentation will be available on Coloplast's website approximately 1 hour before the conference call.Please note that the webcast of the conference call will be available during and after the event. Coloplast will b...

October 21, 2024 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
COLO B Coloplast A/S C...

Coloplast (Hold, TP: DKK950.00) - Focus on the 2024/25 guidance

We expect Coloplast to reach its 2023/24 guidance, with Q4 organic revenue growth of 8.0% driven by the Chronic Care segment, and an EBIT margin before special items of 27.6% (consensus 27.5%). We look for 2024/25 guidance of 8–9% organic revenue growth and a 28–29% EBIT margin. The LCD policy decision is due at end-2024 (we assume the inclusion of Kerecis). We reiterate our HOLD, but have cut our target price to DKK950 (1,000).

COLO B COLOPLAST A/S CLASS B
10/16/24 October 16, 2024 1 EN
Anthony Dick ... (+3)
  • Anthony Dick
  • Emira Sagaama
  • Michael Foundoukidis
CON CONTINENTAL AKT...
ERIC B Telefonaktiebol... ... (+8)

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 15/10/2024

With the recall behind us we believe its time to look forward. Ignoring the noise from the recall over the last years, we believe Philips performance was good. Moreover the company’s positioning in IGT, Monitoring, Cardio Ultrasound and MRI has never been better. There is a credible self-help plan to lift Adj EBITA by 70% over the coming 5 years which should position margins and returns at industry average. The discount to the sector is no longer warranted. We upgrade to outperform. - ...

CON CONTINENTAL AKTIENGESELLSCHAFT
ERIC B TELEFONAKTIEBOLAGET LM ERICSSON CLASS B
AMUN AMUNDI SA
TEP TELEPERFORMANCE SE
COLO B COLOPLAST A/S CLASS B
AD KONINKLIJKE AHOLD DELHAIZE N.V.
DSFIR KONINKLIJKE DSM N.V.
AGN AEGON N.V.
10/15/24 October 15, 2024 1 FR
Anthony Dick ... (+3)
  • Anthony Dick
  • Emira Sagaama
  • Michael Foundoukidis
CON CONTINENTAL AKT...
ERIC B Telefonaktiebol... ... (+8)

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/15/2024

With the recall behind us we believe its time to look forward. Ignoring the noise from the recall over the last years, we believe Philips performance was good. Moreover the company’s positioning in IGT, Monitoring, Cardio Ultrasound and MRI has never been better. There is a credible self-help plan to lift Adj EBITA by 70% over the coming 5 years which should position margins and returns at industry average. The discount to the sector is no longer warranted. We upgrade to outperform. - ...

CON CONTINENTAL AKTIENGESELLSCHAFT
ERIC B TELEFONAKTIEBOLAGET LM ERICSSON CLASS B
AMUN AMUNDI SA
TEP TELEPERFORMANCE SE
COLO B COLOPLAST A/S CLASS B
AD KONINKLIJKE AHOLD DELHAIZE N.V.
DSFIR KONINKLIJKE DSM N.V.
AGN AEGON N.V.
10/15/24 October 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch